Johnson & Johnson: Big Pharma's Q2 2010 Earnings Report

FiercePharma says: Johnson & Johnson met analyst expectations for second-quarter adjusted earnings at $1.21 per share, or $3.45 billion in profits. But its worldwide pharma sales grew by less than 1 percent, and its embattled consumer-drugs segment--which is dealing with manufacturing issues--saw sales fall more than 5 percent to $3.6 billion. J&J cut its profits forecast for the year to $4.65 to $4.75 per share, down from the $4.80 to $4.90 it had predicted in April. The company says part of that decrease stems from currency effects. But it also cited those recalls--and the shutdown of a key consumer-drugs factory, which is keeping a slew of top products such as Tylenol and Motrin off the shelves.


  • Sales of $15.3 Billion
  • Increased 0.6% Versus 2009 Second-Quarter
  • EPS was $1.23 Excluding Special Items
  • 2010 Second-Quarter EPS was $1.21, an increase of 5.2%

See J&J's current stock quote from CNN Money

J&J's website:
J&J's full earnings release: J&J release



Johnson & Johnson: Big Pharma's Q2 2010 Earnings Report

Suggested Articles

Perrigo is treading water in its specialty drugs reinvention plan. Could a merger with another struggling drugmaker—à la Pfizer and Mylan—be the cure?

AveXis' ex-CSO is "prepared to assert his rights and defend his conduct accordingly," a statement from a lawyer who recently represented Elon…

Hikma says it has picked up some pipeline products and nasal and sublingual spray equipment from Insys Therapeutics' bankruptcy.